Aim immunotech announces clinical trial agreement for a phase 2a human challenge trial of ampligen as a potential intranasal prophylaxis against respiratory viruses

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in q4; aim anticipates that the trial will commence shortly thereafter the governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in q4; aim anticipates that the trial will commence shortly thereafter
AIM Ratings Summary
AIM Quant Ranking